<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="237">
  <!-- This xml conforms to:  http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>Information obtained from ClinicalTrials.gov on October 20, 2011</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01228331</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000686545</org_study_id>
    <secondary_id>GPOH-COALL-08-09</secondary_id>
    <secondary_id>EUDRACT-2009-012758-18</secondary_id>
    <secondary_id>EU-21076</secondary_id>
    <nct_id>NCT01228331</nct_id>
  </id_info>
  <brief_title>Clofarabine or High-Dose Cytarabine, Pegaspargase, and Combination Chemotherapy Followed by Daunorubicin Hydrochloride or Doxorubicin Hydrochloride in Treating Young Patients With Acute Lymphoblastic Leukemia</brief_title>
  <official_title>A Randomized Multi-Center Treatment Study (COALL 08-09) to Improve the Survival of Children With Acute Lymphoblastic Leukemia on Behalf of the German Society of Pediatric Hematology and Oncology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <authority>Unspecified</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer
      cells, either by killing the cells or by stopping them from dividing. Giving more than once
      drug (combination chemotherapy) may kill more cancer cells. Radiation therapy uses
      high-energy x-rays to kill cancer cells. It is not yet known whether giving clofarabine or
      high-dose cytarabine, pegaspargase, and combination chemotherapy followed by daunorubicin
      hydrochloride or doxorubicin hydrochloride is more effective in treating young patients with
      acute lymphoblastic leukemia.

      PURPOSE: This randomized phase II/III trial is studying the side effects of giving
      clofarabine compared with giving high-dose cytarabine, pegaspargase, and combination
      chemotherapy followed by daunorubicin hydrochloride or doxorubicin hydrochloride and to see
      how well it works in treating young patients with T-cell acute lymphoblastic leukemia or
      precursor B-cell acute lymphoblastic leukemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To investigate the safety and efficacy of clofarabine combined with pegaspargase in
           patients with high-risk acute lymphoblastic leukemia during the first phase of the
           study. (Phase II)

        -  To investigate, in terms of minimal-residual disease (MRD), the cytotoxic efficacy of
           clofarabine compared with high-dose cytarabine in combination with pegaspargase in
           these patients. (Phase III)

        -  To compare the incidence of infectious complications after the administration of
           daunorubicin hydrochloride versus doxorubicin hydrochloride during reinduction.

      Secondary

        -  To compare the safety profiles of clofarabine and pegaspargase versus high-dose
           cytarabine and pegaspargase in these patients.

        -  To compare, in terms of MRD, the efficacy of clofarabine and pegaspargase and high-dose
           cytarabine and pegaspargase, respectively, versus methotrexate, cyclophosphamide, and
           asparaginase in study GER-COALL-07-03, the historical control group (retrospective
           comparison).

        -  To determine the influence of MRD-based stratification in COALL-09 on overall survival
           and event-free survival in a historical comparison of previous COALL studies.

      OUTLINE: This is a multicenter, sequential phase II/III study. Patients are stratified to
      low risk (LR) or high risk (HR) depending on peripheral white blood cell count on diagnosis,
      age on diagnosis, and immunological subtype. Patients undergo 2 randomizations (1 during
      intensification and 1 during reinduction) in the study.

        -  Preliminary treatment: All patients receive daunorubicin hydrochloride IV over 24 hours
           on day -7 and methotrexate intrathecally (IT) once on day -9, -8, or -7.

        -  Induction: All patients receive vincristine IV on days 1, 8, 15, and 22; daunorubicin
           hydrochloride IV over 24 hours on days 1, 8, and 15; and oral prednisone 3-4 times
           daily on days 1-28.

      Patients are assessed for minimal-residual disease (MRD) status after induction phase.
      Patients not in remission on day 29 are treated off study. Patients with LR disease are
      further stratified to LR-reduced (LR-R), LR-standard (LR-S), and LR-intensified (LR-I)
      groups; patients with HR disease are further stratified to HR-reduced (HR-R), HR-standard
      (HR-S), and HR-intensified (HR-I) groups. Patients in the LR-R and HR-R groups do not
      undergo randomization during study.

        -  Intensification (randomization 1): Patients receive therapy according to risk and
           disease subtypes. Some patients in different risk group are randomized* to receive
           high-dose (HD) cytarabine and pegaspargase or clofarabine and pegaspargase.

             -  LR-R and LR-S: Patients receive medium-high-dose (mHD) methotrexate IV over 24
                hours on days 50, 64, and 78; etoposide phosphate IV over 1-2 hours and cytarabine
                IV over 1 hour on day 66; oral mercaptopurine on days 50-56 and 78-120; oral
                thioguanine on days 64-70; and methotrexate IT on days 29, 50, 64, and 78.
                Patients in LR-S group who still have a detectable MRD load on day 29 are
                randomized (randomization 1) to 1 of 2 arms to receive cytarabine and pegaspargase
                vs. clofarabine and pegaspargase.

                  -  Arm I (cytarabine and pegaspargase) Patients receive HD cytarabine IV over 3
                     hours twice daily on days 29-31 and pegaspargase IV over 2 hours on days 31,
                     52, and 80.

                  -  Arm II (clofarabine and pegaspargase) Patients receive clofarabine IV over 2
                     hours on days 29-33 and pegaspargase IV over 2 hours on days 33, 52, and 80.

             -  LR-I and precursor B-cell acute lymphoblastic leukemia (ALL) HR-S and HR-I:
                Patients receive cyclophosphamide IV over 30 minutes on days 50 and 64; mHD IV
                over 24 hours on days 51, 65, 78, and 92; etoposide phosphate IV over 1-2 hours
                and cytarabine IV over 1 hour on days 80 and 94; oral mercaptopurine on days 64-70
                and 92-98; oral thioguanine on days 78-84; and methotrexate IT on days 29, 51, 65,
                78, and 92. All precursor B-cell ALL patients with a detectable MRD load on day 29
                and T-cell ALL patients with an MRD load ≥ 10³ on day 29 are randomized*
                (randomization 1) to 1 of 2 arms to receive cytarabine and pegaspargase vs.
                clofarabine and pegaspargase.

                  -  Arm I (cytarabine and pegaspargase) Patients receive HD cytarabine IV over 3
                     hours twice daily on days 29-31 and 106-108 and pegaspargase IV over 2 hours
                     on days 31, 53, 67, and 108.

                  -  Arm II (clofarabine and pegaspargase) Patients receive clofarabine* IV over 2
                     hours on days 29-33 and pegaspargase IV over 2 hours on days 33, 53, 67, and
                     108.

             -  NOTE: *In phase II, all patients with an MRD load of ≥ 104 (on day 29) receive
                clofarabine and pegaspargase without randomization.

             -  T-cell ALL HR (HR-R, HR-S, and HR-I): Patients receive cyclophosphamide IV over 30
                minutes on days 29 and 64; mHD methotrexate IV over 24 hours on days 30, 65, 78,
                and 92; etoposide phosphate IV over 1-2 hours and cytarabine IV over 1 hour on
                days 80 and 94; oral mercaptopurine on days 64-70 and 92-98; oral thioguanine on
                days 78-84; and methotrexate IT on days 30, 43, 65, 78, and 92. Patients in HR-S
                and HR-I group are randomized* (randomization 1) to 1 of 2 arms to receive
                cytarabine and pegaspargase vs. clofarabine and pegaspargase.

                  -  Arm I (cytarabine and pegaspargase): Patients receive HD cytarabine IV over 3
                     hours twice daily on days 43-45 and 106-108 and pegaspargase IV over 2 hours
                     on days 32, 45, 67, and 108.

                  -  Arm II (clofarabine and pegaspargase): Patients receive clofarabine IV over 2
                     hours on days 43-47 and pegaspargase IV over 2 hours on days 32, 47, 67, and
                     108.

      Patients in HR-I group also receive amsacrine IV over 4 hours and etoposide phosphate IV
      over 2 hours on days 127 and 128, methylprednisolone IV over 30 minutes on days 127-130, and
      methotrexate IT on day 127, at the end of intensification.

      NOTE: *In phase II, all patients with an MRD load of ≥ 103 (on day 43) receive clofarabine
      and pegaspargase without randomization.

        -  CNS therapy: All patients with initial CNS involvement undergo cranial radiotherapy for
           a total of 12 or 18 Gy. HR patients (precursor B-cell ALL with initial WBC count ≥
           200/nL and T-cell ALL with initial WBC count ≥ 100/nL) with no initial CNS involvement
           also undergo cranial radiotherapy for a total of 12 Gy, beginning 2-3 weeks after the
           last dose of HD cytarabine or clofarabine. LR patients and HR patients (precursor
           B-cell ALL with initial WBC count &lt; 200/nL and T-cell ALL with initial WBC count &lt;
           100/nL) with no initial CNS involvement do not receive initial cranial radiotherapy. At
           the beginning of CNS therapy, before cranial radiotherapy, HR-I patients receive
           vincristine IV on day 1; doxorubicin hydrochloride IV over 24 hours on day 1; oral
           dexamethasone 3 times daily on days 1-7; and pegaspargase IV over 2 hours on day 7.

      All patients receive interim therapy comprising 3 doses (2 in week 1 and 1 in week 3) of
      methotrexate IT and oral mercaptopurine daily during the 4 weeks between intensification and
      reinduction.

        -  Reinduction (randomization 2): Patients undergo reinduction immediately after
           completion of interim therapy. Patients in LR-S, LR-I, HR-S, and HR-I groups are
           randomized to 1 of 2 arms (doxorubicin hydrochloride vs. daunorubicin hydrochloride)

             -  LR-S: Patients receive vincristine IV on days 1 and 8, oral dexamethasone on days
                1-14, pegaspargase IV over 2 hours on day 9, cyclophosphamide IV over 30 minutes
                on day 22, cytarabine IV or intramuscularly (IM) on days 23-26, oral thioguanine
                on days 22-28, and methotrexate IT on days 1, 22, and 36.

                  -  Arm III (doxorubicin hydrochloride) Patients receive doxorubicin
                     hydrochloride IV over 24 hours on days 1 and 8.

                  -  Arm IV (daunorubicin hydrochloride): Patients receive daunorubicin
                     hydrochloride IV over 24 hours on days 1 and 8.

             -  LR-R and HR-R: Patients are not randomized. They receive vincristine IV on days 1
                and 8, oral dexamethasone on days 1-14, pegaspargase IV over 2 hours on day 8, and
                methotrexate IT on days 1 and 15.

             -  LR-I, HR-S, and HR-I: Patients receive vincristine IV on days 1, 8, 22, and 29;
                oral dexamethasone twice daily on days 1-14 and 22-35; cyclophosphamide IV over 30
                minutes on days 43 and 57; cytarabine IV or IM on days 43-46 and 57-60; oral
                thioguanine on days 43-49 and 57-63; and methotrexate IT* on days 1, 22, and 43.

                  -  Arm III (doxorubicin hydrochloride) Patients receive doxorubicin
                     hydrochloride IV over 24 hours on days 1, 8, 22, and 29.

                  -  Arm IV (daunorubicin hydrochloride) Patients receive daunorubicin
                     hydrochloride IV over 24 hours on days 1, 8, 22, and 29.

      NOTE: *Patients who underwent cranial radiotherapy do not receive methotrexate IT.

        -  Maintenance: Beginning 2-3 weeks after reinduction, all patients receive oral
           mercaptopurine daily and oral methotrexate weekly for 2 years. Except for LR-R and
           HR-R, patients also receive pegaspargase IV over 2 hours every 3 weeks for 3 doses.
           Patients who have not undergone CNS radiotherapy receive methotrexate IT at 3, 6, and 9
           months.

      Blood and bone marrow samples may be collected periodically for research studies.

      After completion of study treatment, patients are followed monthly for 1 year, every 3
      months for 2 years, every 6 months for 2 years, and then annually for 5 years.

      PROJECTED ACCRUAL: A total of 41 high-risk patients will be accrued for phase II, 296
      patients for the first randomization (phase III), and 396 patients for the second
      randomization will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2010</start_date>
  <primary_completion_date type="Anticipated">September 2016</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation:  Randomized, Masking:  Open Label, Primary Purpose:  Treatment</study_design>
  <primary_outcome>
    <measure>Safety and efficacy of clofarabine combined with pegaspargase (phase II)</measure>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Cytotoxic efficacy of clofarabine compared with high-dose (HD) cytarabine in combination with pegaspargase  (phase III)</measure>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of infectious complications after administration of daunorubicin hydrochloride vs doxorubicin hydrochloride</measure>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety profiles of clofarabine and pegaspargase vs HD cytarabine and pegaspargase</measure>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of clofarabine and pegaspargase and HD cytarabine and pegaspargase, in terms of  minimal-residual disease    (MRD) vs methotrexate, cyclophosphamide, and asparaginase in study COALL-07-03</measure>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of MRD-based stratification in COALL-09 on overall survival and event-free survival in a historical comparison of previous COALL studies</measure>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">660</enrollment>
  <condition>Leukemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>amsacrine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clofarabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>daunorubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide phosphate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mercaptopurine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methylprednisolone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pegaspargase</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thioguanine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>whole-brain radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of precursor B-cell acute lymphoblastic leukemia (ALL) or T-cell ALL* after
             October 1st 2009

               -  No B-cell ALL NOTE: *Patients with non-Hodgkin lymphoma of the T-cell or B-cell
                  precursor type are included in the observation group.

          -  Meets 1 of the following risk group criteria:

               -  Low-risk (LR) disease meeting all of the following criteria:

                    -  WBC &lt; 25/nL at diagnosis

                    -  Age ≥ 1 to &lt; 10 years

                    -  Common ALL or precursor B-cell ALL

                    -  Complete remission on day 29 (after induction therapy)

                    -  No 11q23 rearrangement

                    -  No hypodiploid chromosome number

               -  High-risk (HR) disease meeting any of the following criteria:

                    -  WBC ≥ 25/nL at diagnosis

                    -  Age ≥ 10 years

                    -  Progenitor B-cell ALL or T-cell ALL

                    -  No complete remission on day 29

                    -  11q23 rearrangement

                    -  Hypodiploid chromosome number (&lt; 45 chromosomes)

          -  Must meet 1 of the following criteria regarding minimal-residual disease (MRD):

               -  LR disease after induction (on day 29):

                    -  LR-reduced (LR-R): MRD negative

                    -  LR-standard (LR-S): MRD positive but &lt; 10^-3 or no evaluable MRD results

                    -  LR-intensified (LR-I): MRD ≥ 10^-3

               -  HR disease after induction and intensification ????? (on day 29 and/or day 43):

                    -  HR-reduced (HR-R):

                         -  T-cell ALL: MRD &lt; 10^-3 on day 29

                         -  Precursor B-cell ALL: MRD negative on day 29

                    -  HR-standard (HR-S):

                         -  T-cell ALL: MRD ≥ 10^-3 on day 29 and &lt; 10^-3 on day 43

                         -  Precursor B-cell ALL: MRD positive on day 29 but &lt; 10^-3 or no
                            evaluable MRD results

                    -  HR-intensified (HR-I):

                         -  T-cell ALL: MRD ≥ 10^-3 on day 43

                         -  Precursor B-cell ALL: MRD ≥ 10^-3 on day 29

          -  Must be under treatment at 1 of the participating hospitals

          -  No disease that is a secondary malignancy or relapsed

          -  After induction, patients with translocation t(9;22) will receive treatment as part
             of the European Study on Philadelphia-positive leukemia (EsPhALL)

          -  bcr-abl-positive patients will be assigned and treated according to different
             protocols

        PATIENT CHARACTERISTICS:

          -  No prior severe illness that makes treatment on this study impossible from the outset

               -  Trisomy 21 (Down syndrome) allowed

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  No prior cytostatic treatment lasting &gt; 7 days

          -  No prior treatment with drugs other than vincristine sulfate, daunorubicin
             hydrochloride, and prednisone
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Horstmann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Hamburg-Eppendorf</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Krankenanstalten Gilead gCmbH Neurochirurgische Klinik</name>
      <address>
        <city>Bielefeld</city>
        <zip>33617</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>49-521-144-2728</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Bremen-Mitte</name>
      <address>
        <city>Bremen</city>
        <zip>D-28205</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>49-421-497-5413</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Duesseldorf</name>
      <address>
        <city>Duesseldorf</city>
        <zip>D-40225</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>49-211-81-17662</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinik und Poliklinik Fuer Kinder-und Jugendmedizin - Universitaetsklinikum Greifswald</name>
      <address>
        <city>Greifswald</city>
        <zip>17487</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>49-3834-86-6321</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Medical Center Hamburg - Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>D-20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>49-407-4105-2580</phone>
      <email>horstmann@uke.uni-hamburg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinic for Bone Marrow Transplantation and Hematology and Oncology</name>
      <address>
        <city>Idar-Oberstein</city>
        <zip>D-55743</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>49-6781-66-1582</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Krefeld GmbH</name>
      <address>
        <city>Krefeld</city>
        <zip>D-47805</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>49-2151-322-375</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaets - Kinderklinik</name>
      <address>
        <city>Leipzig</city>
        <zip>D-04317</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>49-341-9726-113</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Johannes Gutenberg University</name>
      <address>
        <city>Mainz</city>
        <zip>D-55101</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>49-6131-17-2642</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Staedtisches Krankenhaus Muenchen - Harlaching</name>
      <address>
        <city>Munich</city>
        <zip>D-81545</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>49-89-6210-2720</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dr. von Haunersches Kinderspital der Universitaet Muenchen</name>
      <address>
        <city>Munich</city>
        <zip>D-80337</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>49-89-5160-2843</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinik St. Hedwig-Kinderklinik</name>
      <address>
        <city>Regensburg</city>
        <zip>93049</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>49-941-2080-493</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dr. Horst-Schmidt-Kliniken</name>
      <address>
        <city>Wiesbaden</city>
        <zip>D-65199</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>49-611-43-2564</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Helios Kliniken Wuppertal University Hospital</name>
      <address>
        <city>Wuppertal</city>
        <zip>D-42283</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>49-202-896-2444</phone>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://cancer.gov/clinicaltrials/GPOH-COALL-08-09</url>
    <description>Clinical trial summary from the National Cancer Institute's PDQ® database</description>
  </link>
  <verification_date>October 2010</verification_date>
  <lastchanged_date>November 5, 2010</lastchanged_date>
  <firstreceived_date>October 23, 2010</firstreceived_date>
  <keyword>T-cell childhood acute lymphoblastic leukemia</keyword>
  <keyword>untreated childhood acute lymphoblastic leukemia</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>6-Mercaptopurine</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Thioguanine</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Pegaspargase</mesh_term>
    <mesh_term>Clofarabine</mesh_term>
    <mesh_term>Amsacrine</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
</clinical_study>
